Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Latest news
28 Sep, 2022
Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts
16 Aug, 2022
Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral
12 May, 2022
Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
Meet the team
Douglas Thomson
Chief Executive Officer
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board
Mark R. Bamforth
Non-executive Director